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Background: There is a body of evidence that shows a link between tumorigenesis and ribosome biogenesis. The
precursor of mature 18S, 28S and 5.8S ribosomal RNAs is transcribed from the ribosomal DNA gene (rDNA), which
exists as 300–400 copies in the human diploid genome. Approximately one half of these copies are epigenetically
silenced, but the exact role of epigenetic regulation on ribosome biogenesis is not completely understood. In this study
we analyzed the methylation profiles of the rDNA promoter and of the 5’ regions of 18S and 28S in breast cancer.
Methods: We analyzed rDNA methylation in 68 breast cancer tissues of which the normal counterpart was partially
available (45/68 samples) using the MassARRAY EpiTYPER assay, a sensitive and quantitative method with single base
resolution.
Results: We found that rDNA locus tended to be hypermethylated in tumor compared to matched normal breast
tissues and that the DNA methylation level of several CpG units within the rDNA locus was associated to nuclear grade
and to nucleolar size of tumor tissues. In addition we identified a subgroup of samples in which large nucleoli were
associated with very limited or absent rDNA hypermethylation in tumor respect to matched
normal tissue.
Conclusions: In conclusion, we suggest that rDNA is an important target of epigenetic regulation in breast tumors and
that rDNA methylation level is associated to nucleolar size.Background
Epigenetic regulation of ribosomal DNA (rDNA) locus
has a pivotal role in orchestrating ribosome biogenesis.
Human cells contain about 400 copies of the ribosomal
RNA (rRNA) genes organized as tandem, head-to-tail re-
peats [1,2], which are located in the fibrillar centers and
the dense fibrillar component of the nucleolus [3]. Each
unit is ~43 kb long and includes the 47S rRNA encoding
sequence (~13 kb) and a non-transcribed intergenic spa-
cer (~30 kb). In physiological conditions, around half of
these copies is allelically inactivated through a combin-
ation of epigenetic mechanisms including late replication
time [4], specific repression factors [5,6] and methylation
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unless otherwise stated.promoter region, extending from −50 to +20 in respect to
the transcription starting site (TSS), and an upstream con-
trol element (UCE) at −200 in respect to TSS. In humans,
but not in rodents, both the UCE and the core promoter
are CpG rich regions, classifiable as CpG islands, which
usually show a complex methylation pattern [7,8] that can
affect rRNA expression [9,10].
Bisulfite sequencing of clonal rDNA promoters has
been used to characterize rDNA methylation status in sev-
eral pathological conditions. Hypermethylation of rDNA
promoter was described in brain from Alzheimer’s disease
[11] and suicide subjects [12], while methylation levels of
18S and 28S 5’ regions were decreased in white blood cells
from systemic lupus erythematosus subjects [13]. rDNA
hypermethylation occurs during aging [14], and accord-
ingly accelerated methylation of ribosomal regions was
shown in fibroblasts from subjects affected by Werner syn-
drome [15]. The analysis of rDNA methylation in tumor
samples appears to be in this context of extreme interest.l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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the increased demand for protein synthesis, a prerequis-
ite for cell growth and cell proliferation [16,17], and, as
consequence, the rate of ribosome production is not-
ably enhanced in cancer cells. rDNA promoter was found
hypomethylated in respect to corresponding normal tissue
in human hepatocellular carcinomas [7] but not in pros-
tate cancer [18]. On the contrary, Yan and colleagues
used methylation-sensitive Southern blotting to show
increased rDNA methylation in patients with breast cancer
compared to the normal control tissue; rDNA hypermethy-
lation resulted also in association with specific tumor fea-
tures such as the negativity of oestrogen receptors and poor
tumor differentiation status [19].
In this study we analyzed methylation levels of three
different regions within rDNA genes (the promoter and
5’ regions of 18S and 28S sequences). In order to pre-
cisely define rDNA methylation profiles in breast cancer
we used the MassARRAY EpiTYPER assay, a more sensi-
tive and quantitative method compared to Southern blot
and to clonal sequencing. Furthermore, we investigated a
possible correlation between the methylation status of sin-
gle CpG sites, ribosomal biogenesis and the available clin-
ical and bio-pathological parameters in order to define its
possible impact in the biological and clinical behavior of
the tumors.
Methods
Patient materials, characterization and total DNA
extraction
The study was approved by the St Orsola-Malpighi Hospital’s
ethical review board (approval number 75/2011/U/TESS).
All volunteers provided written, informed consent. Sixty
eight breast carcinomas were selected from a series of
consecutive patients who had undergone surgical re-
section for primary breast carcinoma at the Surgical
Department of the University of Bologna between 2005
and 2012, on the sole basis of frozen tissue availability. For
forty five patients we collected both tumoral and non
tumoral adjacent tissues (later on named normal tissue).
Each patient’s clinical information was recorded and
correspondent tissue was histologically characterized by a
team of clinical pathologists to define its bio-pathological
features according to standard criteria for both clinical
parameters and TNM (Tumour-Nodal-Metastasis) classi-
fication [20]. The expression of the oncosuppressor
protein p53, Estrogen and Progesteron Receptors (ER
and PR respectively) and proliferative markers ki67 was
measured by experts after specific immunohistochemi-
cal (IHC) staining at the Operative Unit of Anatomy,
Pathological Histology of the Sant’Orsola-Malpighi
University Hospital in Bologna using NovoLinkTM Polymer
Detection System (Novocastra Laboratories Ltd.) and fol-
lowing the manufacturer’s instruction. For IHC analysis,the following mouse monoclonal primary antibodies were
used: p53 (1:400, Novocastra); ER (1:450, DakoCytomation,
Glostrup, Denmark); PR (1:400, Novocastra); ki67 (1:200,
Novocastra). Silver staining of Nucleolar Organizer re-
gions (AgNORs) was performed as described below. Spe-
cimen collection and tissue analyses were approved by the
Bologna University Ethical Committee on human tissues
research. Tissues were preserved at −80°C until use. A
piece of 60 mg for each sample was minced in liquid nitro-
gen and then lysed for total DNA extraction using buffers
provided with NucleoSpinTissue Columns kit (Macherey
Nagel) and following the manufacturer’s instructions.
EpiTYPER assay for quantitative DNA methylation analysis
Quantitative DNA methylation analysis of rDNA locus was
performed using the EpiTYPER assay (Sequenom). Briefly,
1000 ng of DNA were bisulphite converted using the EZ-
96 DNAMethylation Kit (Zymo Research Corporation) as
previously described [21]. 10 ng of bisulphite-treated DNA
were PCR-amplified using the following primers: Ribo
forward: AGGAAGAGAGGTGTGTTTTGGGGTTGAT
TAGAG; Ribo reverse: CAGTAATACGACTCACTAT
AGGGAGAAGGCTAAAACCCAACCTCTCCAAC; 18S
forward: AGGAAGAGAGGTTTGTTGTTTTTTTTGG
ATGTGG; 18S reverse: CAGTAATACGACTCACTA
TAGGGAGAAGGCTCCTTACCTACCTAATTAATCCT
ACCAA; 28S forward: AGGAAGAGAGGGTATTTAG
TTTTAGATGGAGTTTATTATT; 28S reverse: CAGTA
ATACGACTCACTATAGGGAGAAGGCTAAAAAAA
ACTAACCAAAATTCCC. For each gene, CpG sites
with missing values in more than 20% of the samples
were removed, as well as samples with missing values in
more than 20% of CpG sites.
Selective nucleolar staining
Five-micron sections were processed to perform the sil-
ver staining to visualize the nucleolar organizer regions
and the argyrophilic proteins according to the guidelines
of the “International committee on AgNOR quantitation”
[22]. Tissues were deparaffinized in xylene and rehydrated
in decreasing concentrations of ethanol and distilled
water. After antigen retrieval in citrate buffer pH 6.0 at
120°C, 1 atm for 21 minutes, the sections were then incu-
bated in silver nitrate solution in a dark for 13 min at
37°C. The silver staining solution consisted of one part of
silver nitrate (Diapath) and two parts of 2% gelatin (Sigma)
in 1% formic acid (Carlo Erba) solution. Ultra pure dis-
tilled water was used for preparation of all solutions. The
sections were then washed in distilled water, dehydrated
in graded alcohol and xylene and cover slipped. The tissue
was then ready for counts. After silver-staining, the NORs
can be easily identified as black dots exclusively localized
throughout the nucleolar area. Silver stained section was
examined through a light microscope using Image-Pro
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analysis was performed on a cell by cell basis of at least
200 nuclei and the mean nucleolar area was calculated.
The best cutoff value for the nucleolar size variable was
obtained by the receiver operating characteristic curve
and corresponded to the value of 5 μm2.
Statistical analysis
DNA methylation values resulting from EpiTYPER assay
are reported as continuous values ranging from 0 (0%
of methylation) to 1 (100% of methylation). All analyses
were performed in R 2.14. For continuous parameters,
the following thresholds were used in ANOVA and
chi-squared tests: age > 50 years; diameter > 20 mm;
p53 > 10% of positivity; Ki67 > 20% of positivity; nucle-
olar size > 5 μm2. p-values < 0.05 were regarded as statisti-
cally significant.
Results
Characterization of rDNA target regions
To profile the rDNA methylation status in breast cancer,
genomic DNA was extracted from 68 breast carcinomas
samples; for 45 of them, pair-matched normal tissues
were available.
We used the MassARRAY EpiTYPER system to analyze
the methylation status of three target regions (ampli-
cons) in the rRNA gene (Figure 1): i) RiboPromoter,
from position −186 to position +48 (respect to the
transcription start site), including both the upstream
and the core promoters of the gene; ii) 18S, from position +
2946 to position +3432, encompassing the 5’-sequenceFigure 1 Location of the target regions selected for DNA methylation
representation of the rDNA locus and the location of the 3 target regions (
MassARRAY EpiTYPER assay. Base positions are relative to the transcription
amplified strand is indicated, together with the sequence of the unconvert
assessed by the MassARRAY EpiTYPER assay are reported in bold. Abbreviat
spacer 1; ITS2, Internal transcribed spacer 2; 3’-ETS, 3’ External transcribed sof the 18S region; iii) 28S, from position +7297 to pos-
ition +7579, encompassing the 5’-sequence of the 28S
region. The three selected regions partially overlap with
those previously analyzed in other studies [13,23].
The EpiTYPER assay returns quantitative methylation
estimates of single CpGs or of small groups of adjacent
CpGs (CpG units) depending on the sequence context.
Using this method, we measured methylation levels of
8 CpG units (13 CpGs), 14 CpG units (26 CpGs) and
10 CpG units (15 CpGs) in RiboPromoter, 18S and
28S target regions respectively. In RiboPromoter ampli-
con, 7 CpGs were in the UCE region, while the remaining
6 were in the core promoter. The CpG units RiboPromoter_
CpG_15.16 (UCE region) and 18S_CpG_6.7 did not
pass quality controls and were removed from further
analysis.
Assessment of rDNA methylation in normal and tumor
tissues
We first considered the correlation between methylation
values in the 45 samples for which both tumor and nor-
mal tissue were available (Figure 2A). As expected, most
of the CpG units within the same target region showed
high correlation. In addition, comparable high levels of
correlation were detected also between CpG units in dif-
ferent amplicons, although they are several thousands of
bases apart. Correlation levels were slightly but statisti-
cally significantly lower in tumor in respect to normal
tissue (mean correlation values = 0.85 and 0.87 for tumor
and normal tissue respectively, paired t-test p-value =
1.36 × 10−10).analysis within the rDNA locus. The picture reports a schematic
RiboPromoter, 18S and 28S) that are amplified and analyzed by the
starting site (+1) of rRNA primary transcript. For each amplicon the
ed target region. The CpG sites whose methylation status can be
ions: 5’-ETS, 5’ external transcribed spacer; ITS1, Internal transcribed
pacer.
Figure 2 DNA methylation of rDNA locus in pair-matched normal and tumor tissues. (A) The correlation matrices of CpG sites analyzed in
the 3 target regions (RiboPromoter, 18S and 28S) are reported for normal (left panel) and tumor (right panel) tissues. (B) The methylation levels of
rDNA CpG sites are reported for 45 pair-matched normal (left panel) and tumor (right panel) tissues. (C) The boxplot compares, for each CpG site
included in the analysis, the DNA methylation levels in 45 normal and tumor tissues.
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tissue pair are graphically represented in Figure 2B. Con-
siderable inter-individual variation was observed for each
CpG unit both in normal and in tumor tissues. Despite
this variability, we found highly significant hypermethyla-
tion in tumor in respect to matched normal breast tissue
for all the analyzed CpGs (paired t-test, p-value ranging
from 7.97 × 10−12 to 0.017 depending on the CpG unit;
Figure 2C). Comparable significant hypermethylation
of rDNA regions in tumors was evident also in the 22
samples with missing normal matched tissue (Additional
file 1: Figure S1).Relationship between rDNA methylation and clinical and
pathological parameters
We recovered data on 66/68 tumors deeply characterized
for clinical and pathological features (listed in Table 1)
and, first of all, we investigated whether there was an asso-
ciation between this dataset and rDNA methylation pro-
files. Tumor samples were classified based on patient’s
age, tumor histotype, size, grade (G), nuclear grade (NG),
p53 status, ER and PR expression and proliferative index
(Ki67) as indicated in Materials and Methods. We did
not find significant differences in methylation status
of rDNA between classes for investigated parameters,
Table 1 Characteristics of the patients involved in the study
Patient characteristics N
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rDNA hypermethylation was observed in NG = 3 sam-
ples respect to NG= 1 and NG= 2 samples (Figure 3A),
with statistically significant differences (ANOVA analysis)
for several CpG units within RiboPromoter; 18S and 28S
(Table 2).
There is evidence that the quantitative distribution of
the nucleolar organizer regions (NORs) after their select-
ive staining with silver is closely related to the rates of
rRNA transcription and of ribosome biogenesis, thus
representing a morphological parameter of the rate of
ribosome biogenesis [24-26]. We therefore focused on
evaluating the relationship between the rate of ribosome
biogenesis estimated by measuring the nucleolar size
after selective silver staining of NORs and rDNA methy-
lation. We successfully silver stained and measured
64/68 breast tissue specimens (Figure 3B). In order to
compare the rDNA methylation levels respect to nucle-
olar size, we divided samples into two groups on the
basis of this parameter: 41 samples showed a nucleolar
area ≤ 5 μm2, whilst for 23 samples it was more than 5.
We found that several CpG units within RiboPromoter,
18S and 28S rDNA regions were differently methylated
between the two groups (Table 2, Figure 3C). For all CpG
units we found that lower levels of rDNA methylation
were associated to a higher rate of ribosome biogenesis
(Figure 3C).
Considering that one of the parameters influencing
nuclear grade classification is the presence of a promin-
ent nucleolus, the results on nucleolar size appear in
conflict with those on nuclear grade, being the average
methylation of several sites of rDNA higher in NG3 tu-
mors. To clarify this issue we evaluated the relationship
between nuclear grade, nucleolar size and rDNA methyla-
tion. As previously observed [27,28], a nucleolar area > 5
occurred more frequently in samples with NG= 3 than in
samples with NG= 1 o NG= 2 (Figure 4A; chi-squared
test p-value = 0.048). Interestingly in NG= 1 and NG= 2
samples rDNA methylation levels were not significantly
related to nucleolar size, while most of the CpG units re-
sulted hypermethylated when a NG= 3 co-occurred with
nucleolar size ≤ 5 μm2 (Figure 4B).
Relationship between nucleolar size and rDNA
methylation differences in tumor-normal tissue pairs
Finally, we investigated whether irrespectively to the ab-
solute value of rDNA methylation in tumor tissue, the
extent of rDNA hypermethylation in tumor compared to
normal matched tissue could be related to nucleolar size.
To this purpose, for each CpG unit we calculated DNA
methylation difference between tumor and matched nor-
mal tissue and performed hierarchical clustering analysis
on these differences values (Figure 5A). Hierarchical clus-
tering classified the 45 samples in 2 groups (indicated as
Table 2 ANOVA test of association between rDNA methylation and clinical and pathological parameters
CpG unit Age Histotype Grade Nuclear grade Diameter pT p53 ER PR Ki67 Nucleolar size
Ribo_CpG_5 0.74 0.16 0.37 0.02 0.89 0.93 0.57 0.67 0.96 0.58 0.04
Ribo_CpG_17.18 0.70 0.12 0.28 0.08 0.70 0.74 0.79 0.62 0.91 1.00 0.09
Ribo_CpG_19.20 0.65 0.11 0.52 0.16 0.67 0.67 0.54 0.91 0.83 0.74 0.04
Ribo_CpG_21 0.72 0.09 0.33 0.13 0.61 0.59 0.55 0.92 0.73 0.77 0.05
Ribo_CpG_22.23 0.70 0.12 0.28 0.08 0.70 0.74 0.79 0.62 0.91 1.00 0.09
Ribo_CpG_24.25 0.92 0.20 0.38 0.04 0.55 0.75 0.57 0.95 0.80 0.88 0.02
Ribo_CpG_26 0.96 0.26 0.73 0.26 0.60 0.67 0.31 0.52 0.42 0.46 0.01
X18S_CpG_1 0.59 0.07 0.45 0.18 0.82 0.73 0.34 0.74 0.91 0.87 0.21
X18S_CpG_2 0.87 0.07 0.47 0.14 0.84 0.87 0.43 0.93 0.82 0.82 0.06
X18S_CpG_4 0.52 0.06 0.40 0.05 0.97 0.85 0.60 0.58 0.88 0.67 0.14
X18S_CpG_5 0.63 0.13 0.39 0.04 0.94 0.94 0.51 0.76 0.99 0.39 0.15
X18S_CpG_9.10 0.86 0.47 0.25 0.04 0.51 0.54 0.46 0.96 0.81 0.85 0.05
X18S_CpG_11.12.13 0.57 0.09 0.17 0.01 0.64 0.85 0.90 0.52 0.75 0.44 0.08
X18S_CpG_14.15.16 0.62 0.13 0.21 0.02 0.96 0.99 0.83 0.54 0.81 0.32 0.20
X18S_CpG_17.18 0.45 0.21 0.34 0.03 0.87 0.82 0.76 0.61 0.90 0.42 0.18
X18S_CpG_26 0.53 0.09 0.45 0.13 0.91 0.72 0.73 0.56 0.86 0.86 0.20
X18S_CpG_28.29 0.54 0.15 0.14 0.01 0.87 0.80 0.80 0.21 0.38 0.27 0.24
X18S_CpG_30.31.32 0.76 0.21 0.22 0.05 0.73 0.79 0.85 0.39 0.64 0.72 0.12
X18S_CpG_35 0.92 0.85 0.99 0.96 0.25 0.26 0.21 0.39 0.39 0.83 0.25
X18S_CpG_36.37.38 0.76 0.21 0.22 0.05 0.73 0.79 0.85 0.39 0.64 0.72 0.12
X28S_CpG_1 0.57 0.12 0.29 0.02 0.78 0.90 0.64 0.80 0.95 0.56 0.06
X28S_CpG_2 0.78 0.63 0.62 0.86 0.79 0.73 0.19 0.14 0.19 0.16 0.10
X28S_CpG_3 0.41 0.13 0.45 0.13 0.79 0.81 0.81 0.55 0.82 0.79 0.14
X28S_CpG_10 0.83 0.11 0.44 0.08 0.54 0.65 0.65 0.88 0.95 0.89 0.07
X28S_CpG_11 0.81 0.25 0.40 0.06 0.93 1.00 0.84 0.81 0.99 0.94 0.08
X28S_CpG_12.13 0.74 0.13 0.46 0.08 0.97 0.89 0.40 0.91 0.60 0.82 0.05
X28S_CpG_15.16.17 0.60 0.21 0.33 0.03 0.82 0.95 0.67 0.79 0.98 0.81 0.08
X28S_CpG_18.19 0.75 0.17 0.46 0.08 0.84 0.83 0.52 0.95 0.80 0.97 0.03
X28S_CpG_20 0.78 0.63 0.62 0.86 0.79 0.73 0.19 0.14 0.19 0.16 0.10
X28S_CpG_29.30 0.75 0.16 0.42 0.08 0.74 0.86 0.46 0.79 0.62 0.78 0.04
p-values less than 0.05 are reported in bold.
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lation of tumor tissue. Interestingly, group B comprised
samples with very limited or absent rDNA hypermethyla-
tion in tumor tissue, indicating that increased rDNA
methylation is not a feature shared by all breast carcin-
omas. Subsequently, we investigated if nucleolar areas
were different in the 2 groups resulting from hierarchical
clustering. ANOVA analysis showed that nucleolar
size was significantly higher in group B samples (smaller
DNA methylation difference in tumor-normal tissue pair,
i.e., lower hypermethylation in tumor samples) respect to
group A samples (higher DNA methylation difference in
tumor-normal tissue pair, i.e. stronger hypermethylation
in tumor samples) (p-value = 0.006; Figure 5B). Similar
results were achieved when only NG = 3 samples wereconsidered (Additional file 2: Figure S2). No statistically
significant differences were observed between group A
and group B when the other clinical and pathological pa-
rameters were considered.
Discussion
DNA methylation is a key regulator of gene expression
and of genome architecture, and defects in its regulation
often occur in several human diseases, including cancer.
As many other types of tumors, up to 50% of cases of
breast cancer show hypomethylation of repetitive DNA
sequences and transposable elements, which substan-
tially contributes to genomic instability [29]. Moreover,
genome-wide studies on tumor tissues and breast cancer
cell lines have reported aberrant hypermethylation of the
Figure 3 Relationship between rDNA methylation and tumor parameters. (A) Mean methylation levels of rDNA CpG sites in tumor samples
divided for nuclear grade (NG). Standard deviation bars are reported. (B) Silver staining of two breast carcinomas. Note the higher quantity of
silver stained nucleolar structures in left panel compared with those in right panel. (C) Mean methylation levels of rDNA CpG sites in tumor
samples divided for nucleolar size values. Standard deviation bars are reported.
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sors [30-33].
In this study, we specifically analyzed the methylation
of rDNA genes in breast cancer tissues. Indeed, altered
regulation of ribosome biogenesis is a common feature
of many cancers, and it has been deeply investigated in
breast tumors [34]. In proliferating cancer cells, the rap-
idity of cell proliferation is strictly dependent on ribo-
some production [24,25,35]. This is one of the major
factors contributing to the growth rate of a tumor mass
inside the host, which is one of the most important
prognostic factors in oncology. In human carcinomas
the association of nucleolar hypertrophy with bad prog-
noses is noteworthy and there is an increasing amount
of data that suggests an active role of the nucleolus in
tumorigenesis [3,36]. In line with this, ribosome synthe-
sis has been also identified as a promising target for an-
tineoplastic therapy [37-44].
The methylation status of rDNA promoter, which is
CpG-rich in human [45-47], was investigated in breast
cancer tissues respect to matched normal tissues. Themethylation of two CpG-rich regions located at the 5’ of
18S and 28S sequences was considered too. Our data indi-
cate an increased rDNA methylation in tumors compared
to normal tissues. Although this finding is unexpected,
as neoplastic transformation should sustain ribosome
biogenesis and therefore rDNA hypomethylation, similar
results have been previously described. Yan and colleagues
showed increased rDNA methylation levels in breast
cancer biopsies compared to normal control tissue and
found that rDNA hypermethylation was associated with
the oestrogen receptor negative and with moderately or
poorly differentiated tumors [19]. The technical approach
employed in this work provided information about overall
methylation status of rDNA, regardless to the epigen-
etic regulation of specific CpG sites [19]. Our results con-
firmed rDNA hypermethylation in breast tumors using
the MassARRAY EpiTYPER assay, a technique that allows
to assess methylation levels with single base resolution
and that is more sensitive and quantitative compared
to Southern blot and to clonal-sequencing of bisulfite-
treated DNA. This approach allowed us to deeply
Figure 4 Relationship between nuclear grade, nucleolar size and rDNA methylation. (A) Classification of the analyzed breast carcinoma
samples depending on NG and nucleolar size values. (B) Mean methylation levels of rDNA CpG sites in tumor samples divided in four classes
depending on NG and nucleolar size values. Standard deviation bars are reported.
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Figure 5 Relationship between ribosome biogenesis and rDNA methylation differences in tumor-normal tissue pairs. (A) For each
normal-tumor tissue pair, DNA methylation differences were calculated and subjected to hierarchical clustering using complete linkage method
and a euclidean distance measure. (B) The boxplot compares nucleolar size values between normal-tumor tissue pairs, subdivided in two groups
on the basis of the results of hierarchical clustering.
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expected, in normal tissues the CpG sites in the pro-
moter showed a strong correlation in their methylation
levels. Moreover, also the methylation status of the CpG
sites within the gene body (18S and 28S regions) resulted
highly correlated, suggesting a tight control over the
entire region in normal conditions. Correlation levels
were slightly but significantly lower in tumor samples
respect to normal controls, indicating that a loss in the
epigenetic control, which is a common characteristic of
cancer, occurs also in rDNA region.
Surprisingly, rDNA methylation of normal breast tis-
sues showed substantial inter-individual variation, ran-
ging from 20% to 40% depending on the CpG site. The
biological basis of this strong variability is not clear, al-
though it should be considered that ribosomal biogen-
esis, and potentially also rDNA methylation, is strongly
affected by environmental factors, such as the intracellu-
lar energy status [48].
Yan and coworkers showed that higher rDNA methy-
lation levels in tumor breast tissues were correlated with
ER-negativity and suggested that they could be predictive
of the tumor propensity to hypermethylate ER promoter.
We did not find any significant association between rDNA
methylation and ER status, but it should be considered
that in our cohort ER negative cases were only a minorpart of the samples (11/68 compared to 27/58 in the
work by Yan [19]). On the contrary, significant associ-
ation was found between methylation values of several
sites of rDNA loci and NG and nucleolar size values.
Although only some CpGs reached statistical significance,
the entire locus showed the same trend in terms of DNA
methylation variations, confirming a common regula-
tion of the CpG sites within the region. The nucleolar
size evaluation after its selective staining with silver is
a well established method used in tumor pathology for
tumor characterization, being nucleolar hypertrophy asso-
ciated with bad prognosis. Together with nuclear poly-
morphism, the presence of prominent nucleoli is one of
the parameters influencing NG classification. We ob-
served that a subgroup of samples with NG= 3 but nucle-
olar size ≤ 5 μm2 showed higher rDNA methylation levels,
suggesting that in breast tumors the methylation status of
rDNA loci can affect the rate of ribosome biogenesis and
somehow counteract other adverse pathological condi-
tions. Accordingly, we identified a subgroup of patients in
which the presence of large nucleoli was associated to lim-
ited or absent rDNA hypermethylation of tumor tissue re-
spect to matched normal control. In these tumors the lack
of rDNA hypermethylation could represent an important
factor to cope with the need for a particularly intense bio-
synthetic activity. In addition, this observation confirms
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cancer and indicates that the rate of rDNA hyperme-
thylation can significantly differ between patients. Im-
portantly, samples showing small tumor-normal tissues
differences had higher nucleolar size, indicating that not
only the rDNA methylation level, but also the extent of
rDNA hypermethylation in respect to normal tissue could
represent a marker of breast cancer progression and,
in principle, could be explored as a potential prognos-
tic marker for this tumor type.
rDNA hypermethylation was described in other women’s
cancers, including ovarian cancer [49] and endometrial
carcinoma [50]. The mechanisms and the dynamics that
lead to rDNA hypermethylation in these tumors are not
clear, also because tumor progression should in theory sus-
tain higher levels or ribosome biogenesis, and therefore
rDNA hypomethylation in respect to normal tissue. In all
the cases, higher levels of rDNA methylation were associ-
ated to better prognosis and longer disease-free and overall
survival, suggesting that rDNA methylation could have a
role in the biological and clinical behavior of the tumors.
One intriguing scenario is that rDNA hypermethylation
may be a defense response against tumor progression, but
further analyses are needed to explore this issue. With re-
spect to previous studies, where the relationship between
rDNA methylation and ribosomal biogenesis was not con-
sidered, we demonstrated for the first time that rDNA
methylation is associated to nucleolar size in breast cancer.
Future studies should assess if rDNA methylation affects
the rate of rRNA transcription and therefore the prolifera-
tive potential of tumor cells.
Conclusions
In conclusion, in this study we showed that i) the methy-
lation status of the CpG sites within the rDNA promoter
and the 5’ of 18S and 28S sequences is tightly co-regulated
in normal breast tissue, while in tumor tissue it is slightly
but significantly lower; ii) rDNA methylation tends to be
higher in breast cancer tissues respect to normal counter-
part; iii) rDNA methylation levels are associated to NG
and nucleolar size values and iv) in a subgroup of patients
larger nucleolar size is associated with limited rDNA
hypermethylation in tumor respect to matched normal
tissue.
Additional files
Additional file 1: Supplementary Figure 1. DNA methylation of rDNA
locus in normal and unrelated tumor tissues. The boxplot compares, for
each CpG site included in the analysis, the DNA methylation levels in 45
normal tissues and 23 unrelated tumor samples.
Additional file 2: Supplementary Figure 2. Relationship between
ribosome biogenesis and rDNA methylation differences in tumor-normal
tissue pairs having NG = 3. (A) Only breast carcinomas with NG = 3 were
considered. For each normal-tumor tissue pair, DNA methylationdifferences were calculated and subjected to hierarchical clustering. (B)
The boxplot compares nucleolar size values between normal-tumor tissue
pairs, subdivided in two groups on the basis of the results of hierarchical
clustering.
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